title: Tamsulosin and tolterodine in the medical expulsive therapy for intramural ureteral stones with vesical irritability: a prospective randomized study.
abstract: We performed a randomized, prospective study to assess the possible role of combined tamsulosin and tolterodine therapy for the relief of vesical irritability and in facilitating the spontaneous expulsion of intramural ureteral stones. Patients were randomized to one of three treatment groups. Treatment group 1 patients received tamsulosin 0.4 mg/day, group 2 patients received tamsulosin 0.4 mg/day plus tolterodine 2 mg (twice a day), and group 3 patients received tolterodine 2 mg (twice a day). Subjects rated the urgency associated with each micturition using the Urinary Sensation Scale. Pain descriptions were recorded by the patients using the Visual Analog Scale. Stone expulsion was observed in 30 patients in group 1, 29 patients in group 2 and 18 patients in group 3. Kaplan-Meier curves were plotted to access the expulsion rate of each group over time. A significant difference was shown for the expulsion rate between the tolterodine group and the other two groups. (P = 0.003 by log rank test). Average time to expulsion for groups 1, 2 and 3 was 7.62 ± 2.42, 7.79 ± 2.11 and 10.57 ± 2.71 days, respectively (P = 0.000). In groups 1, 2 and 3, the mean number of pain episodes was 2.27 ± 0.91, 1.39 ± 1.34 and 1.38 ± 1.20, respectively (P = 0.023). Treatment with tamsulosin and tolterodine appears to be beneficial in intramural ureteral stone clearance, particularly in intramural ureter stone with symptoms of vesical irritability.
authors: Department of Urology, Affiliated Jiangning Hospital, Nanjing Medical University, Gushan Road 78, Nanjing, 211100, China, ljlxx01@163.com.
authors: Jian Lin
authors: JL
authors: Lv
authors: Qing lai
authors: Ql
authors: Tang
mesh_terms: D000328:Adult; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D003408:Cresols / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000077409:Tamsulosin; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014514:Ureteral Calculi / Q000188:drug therapy* / Q000503:physiopathology; D064804:Urological Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D013449:Sulfonamides; D064804:Urological Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000077409:Tamsulosin
references: Postgrad Med J. 1964 Apr;40:179-83
references: 14142154
references: Eur Urol. 2008 Feb;53(2):411-8
references: 17889988
references: J Urol. 1994 Oct;152(4):1095-8
references: 8072071
references: Urol Res. 2011 Jun;39(3):213-6
references: 21069309
references: Urology. 2007 Apr;69(4):633-6
references: 17445639
references: J Urol. 2003 Dec;170(6 Pt 1):2202-5
references: 14634379
references: Urology. 2000 Oct 1;56(4):579-82
references: 11018608
references: Eur Urol. 2001 Mar;39(3):241-9
references: 11275712
references: Eur Urol. 2009 Sep;56(3):407-12
references: 19375849
references: Int J Clin Pract. 2006 Jun;60(6):752-8
references: 16805764
references: J Urol. 2004 Aug;172(2):568-71
references: 15247732
references: World J Urol. 2011 Dec;29(6):767-71
references: 21845472
references: Int J Clin Pract. 2006 Jun;60(6):745-51
references: 16805763
references: Eur Urol. 2009 Sep;56(3):455-71
references: 19560860
references: Urol Res. 2012 Dec;40(6):757-62
references: 22926289
references: J Urol. 2005 Jul;174(1):167-72
references: 15947613